None
Conditions
Interventions
Group A (1-3 years old):Fixed artemisia argyi with ketamine 0.5mg/kg and sufentanil 0.1ug/kg
Group B(3-6 years old):Fixed artemisia argyi with ketamine 0.5mg/kg and sufentanil 0.1ug/kg
Group C (6-12 years old):Fixed artemisia argyi with ketamine 0.5mg/kg and sufentanil 0.1ug/kg
Sponsors
Jinan Children's Hospital (Affiliated Children's Hospital of Shandong University)
Eligibility
Sex/Gender
All
Age
1 Years to 12 Years
Inclusion criteria
Inclusion criteria: (1) Children aged 1 to 12 years; (2) Patients with American Society of Anesthesiologists (ASA) physical status classification of grade I or II; (3) Pediatric patients maintaining spontaneous breathing under laryngeal mask airway ventilation.
Exclusion criteria
Exclusion criteria: 1) Children with a body mass index greater than 24 kg/m²; (2) Patients with difficult airways and obstructive sleep apnea syndrome; (3) Patients with a risk of gastroesophageal reflux; (4) Patients allergic to remimazolam or esketamine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ED50 and ED95 of remimazolam ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate, systolic pressure;Adverse respiratory events;Duration of stay PACU; | — |
Countries
China
Contacts
Public ContactWu Yan
Jinan Children's Hospital (Affiliated Children's Hospital of Shandong University)
Outcome results
None listed